Dudediligence.

Jaguar Health, Inc

JAGXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$3.1MSep ’24$3.5MDec ’24$2.2MMar ’25$3.0MJun ’25$3.1MSep ’25$3.2MDec ’25$20.3MMar ’26$1.2MJun ’26
Net income, by quarter
−$9.9MSep ’24−$9.9MDec ’24−$10.5MMar ’25−$10.4MJun ’25−$9.5MSep ’25$30.3MDec ’25$8.7MMar ’26−$12.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$4.3M$12.0M$9.8M$11.7M$11.5M
Gross profit$2.0M$9.9M$7.7M$9.7M$7.7M
Operating income−$40.7M−$34.4M−$34.3M−$30.8M−$45.9M
Net income−$52.6M−$47.5M−$41.3M−$38.5M−$54,000
Operating cash flow−$35.0M−$33.1M−$33.2M−$29.4M−$23.7M
Free cash flow−$35.0M−$33.2Mnone on file−$29.4Mnone on file
Cash$17.1M$5.5M$6.5M$8.0M$968,000
Shares outstanding596.2K1.3M15.4K294.5K2.3M